The molecular profiling of melanoma is nigh. Assessment of advanced-stage, metastatic melanoma to determine whether it carries a mutation in the BRAF oncogene will turn routine soon, once physicians have the option to treat these patients with the new BRAF inhibitor drug, vemurafenib.
That might happen any day now. Reuters said on August 9 that the FDA's approval of vemurafenib could be announced soon. Roche/Genentech submitted their NDA for vemurafenib to the FDA in May, and in June came impressive efficacy results in a phase 3 study that was reported at both ASCO and in a NEJM article.
Courtesy Wikimedia Commons/Nephron/Creative Commons License
Histopathology of metastatic melanoma is shown.
Last week, I covered the American Academy of Dermatology's Summer Academy meeting in New York, where melanoma specialist Richard D. Carvajal from Memorial Sloan-Kettering said that once vemurafenib was on the market genetic analysis of advanced melanomas to findBRAF mutations would suddenly become standard of care